• An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years¹

Represents second approved indication for Restylane Defyne in U.S.

Expands Galderma Aesthetics’ growing Restylane product portfolio

Ad hoc announcement pursuant to Art. 53 LR

Zug, Switzerland, July 23, 2026 – Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026.

DALLAS, Texas, October 3, 2022 /PRNewswire/ -- Galderma announced today its continued partnership with National Breast Cancer Foundation Inc. (NBCF), one of the leading breast cancer organizations in the world.